Trial confirms efficacy of Clinuvel drug in EPP
11 November, 2013 by Dylan Bushell-EmblingClinuvel (ASX:CUV) said its Scenesse drug was able to relieve symptoms and improve quality of life in patients with rare genetic disease EPP during a phase III trial.
Immuron widens scope for liver treatment
08 November, 2013 by Dylan Bushell-EmblingImmuron (ASX:IMC) has received an approval to trial its IMM-124E in ASH as well as NASH, and animal studies support its utility in treating liver fibrosis.
MTAA awards achievements in medical technology
08 November, 2013The Medical Technology Association of Australia (MTAA) last night held its annual conference dinner as part of the MedTech 2013 conference in Sydney, where the association presented two awards for achievements in medical technology.
AusBiotech signs MoU with KoreaBIO
07 November, 2013The AusBiotech 2013 national conference culminated last week in the signing of a memorandum of understanding (MoU) between AusBiotech and the Korea Biotechnology Industry Organization (KoreaBIO).
Personalised medicine
06 November, 2013 by Susan WilliamsonThe investment that has been put into personalised medicine is starting to pay off - the tailored diagnosis, prognosis, treatment and prevention of disease in an individual is beginning to be applied, as David Randerson intends to explain at the conference.
AusBiotech announces new directors at AGM
05 November, 2013AusBiotech has announced the election of two new directors to its board at its annual general meeting in Brisbane last week - Julie Phillips, CEO of BioDiem; and Dr Andrea Douglas, vice president, R&D strategy and portfolio at CSL.
Clinuvel to start new vitiligo trial
05 November, 2013 by Dylan Bushell-EmblingClinuvel (ASX:CUV) is awaiting approval to commence a new phase II trial of Scenesse in vitiligo, to help confirm the positive findings of an earlier trial.
Bioniche names new CEO
05 November, 2013 by Dylan Bushell-EmblingDr Michael Berendt has replaced Bioniche (ASX:BNC) founder Graeme McRae as the company's CEO.
Spruiking for business the UK way
04 November, 2013 by Susan WilliamsonThe UK delegation that attended the recent 2013 AusBiotech meeting is keen to develop its relationship with the Australian biotech sector.
WA biotechs pick up industry and export awards
04 November, 2013 by Dylan Bushell-EmblingClinical trials facility Linear Clinical Research, drug discovery CRO Epichem and sera supplier Serana have all won prizes during this year's Western Australian Industry and Export Awards.
Mesoblast partner cleared for phase III heart trial
04 November, 2013 by Dylan Bushell-EmblingMesoblast's partner Teva Pharmaceutical Industries has secured US FDA approval for a phase III IND trial of Mesoblast's MPCs in congestive heart failure.
Pharmaxis taking up full $42m financing deal
01 November, 2013 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) has elected to receive the full US$40m investment from NovaQuest, to help fund its continuing efforts to achieve US approval for Bronchitol in cystic fibrosis.
Hatchtech hardly a head-scratcher for investors
01 November, 2013 by Dylan Bushell-EmblingHatchtech has raised $12.6m from existing and new investors to support its phase III trials and US NDA for DeOvo, a single-dose headlice treatment.
Surgical device start-up Protego Medical launches
01 November, 2013 by Dylan Bushell-EmblingProtego Medical, a company developing a device to protect the sternum during cardiac surgery, launched yesterday with $2m in MRCF seed funding.
Regeneus stem cell therapy reaches Melbourne
01 November, 2013 by Dylan Bushell-EmblingLinley Clinic Private Hospital has become the first Melbourne clinic to offer Regeneus's (ASX:RGS) HiQCell, a point-of-care cell therapy for musculoskeletal conditions.
